Wednesday, April 19, 2023
Ancora Heart and egnite announced a strategic partnership to accelerate clinical trial enrolment for Ancora Heart’s CORCINCH-HF pivotal clinical trial, to evaluate the safety and efficacy of the AccuCinch® Ventricular Restoration System.
The partnership brings together the cutting-edge technology and expertise of both organisations with the goal of delivering innovative therapies to patients faster. Moreover, this partnership with egnite and The Christ Health Network allow to deploy AI tools such as egnite’s Trial Accelerator and expedite identification of eligible candidates for the CORCINCH-HF trial.
The new development of the AccuCinch System provides a minimally invasive treatment option to further improve the lives of heart failure patients whose symptoms progress despite guideline directed medical therapy.
The innovative solution can accelerate clinical trial enrolment through AI and big data processing, automatically screening hundreds of thousands of patients against trial parameters to help identify more trial candidates without hospital staff dedicating hours to manual chart review.
Identifying patient candidates for clinical trial participation can be a complex task that requires many hours to review medical charts in the search for matching clinical criteria. The use of AI technology streamlines the trial screening process by identifying candidates more quickly and efficiently, thereby freeing up critical resources needed for clinical trial success.
